Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience.

Article Details

Citation

Copy to clipboard

Gerullis H, Wawroschek F, Kohne CH, Ecke TH

Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience.

Ther Adv Urol. 2017 Jan;9(1):28-35. doi: 10.1177/1756287216677903. Epub 2016 Nov 21.

PubMed ID

28042310 [ View in PubMed

]

Abstract

Vinflunine (VFL) has been approved in Europe for second-line treatment of metastatic and advanced urothelial cancer after failure of platin-containing therapy. Since approval, the drug has been investigated in few clinical trials. Most of the currently available reports describe experiences with VFL in a daily clinical setting. This review gives a short overview on clinical experiences and clinical trials involving VFL since the approval of this drug in 2009.

DrugBank Data that Cites this Article

Drugs

Vinflunine

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Vinflunine	Tubulin beta chain	Protein	Humans	Yes	Inhibitor	Details